Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial

…, RJ O'Connell, S Vasan, A Pitisuthitham, Y Sabmee… - The lancet HIV, 2020 - thelancet.com
Background The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521)
and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in …

[HTML][HTML] Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised …

…, I Mena, M Meseck, B Phonrat, Y Sabmee… - …, 2022 - thelancet.com
Background Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low-
and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based …

[HTML][HTML] Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen …

…, C Sirivichayakul, A Pitisuthitham, Y Sabmee… - …, 2021 - thelancet.com
Background Recombinant pertussis vaccines inducing long-lasting immune responses could
help to control the rise in pertussis. We here report on persisting antibody responses 2 and …

Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a …

…, K Boonnak, K Lapphra, Y Sabmee… - The Lancet Infectious …, 2018 - thelancet.com
Background The immunogenicity of acellular pertussis vaccines and persistence of immunity
after vaccination might be improved by using genetically inactivated pertussis toxin (PTgen) …

A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2 …

…, K Boonnak, K Lapphra, Y Sabmee… - The Lancet Infectious …, 2018 - thelancet.com
Background Increasing evidence shows that protection induced by acellular pertussis
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease. We …

Issues in women's participation in a phase III community HIV vaccine trial in Thailand

…, P Thongcharoen, R Pawarana, Y Sabmee… - AIDS Research and …, 2013 - liebertpub.com
To assess qualities and outcomes of women participating in a large, community-based HIV
vaccine trial, the present study was conducted among female participants of the RV 144 prime…

Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding

K Khowsroy, J Dhitavat, Y Sabmee… - AIDS Research and …, 2014 - liebertpub.com
A Phase III community-based HIV vaccine trial using the ALVAC-HIV and AIDSVAX B/E
prime-boost regimen (RV144) showed a modest vaccine efficacy of 31.2% against HIV …

[PDF][PDF] A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a …

W Phongsamart, K Boonnak, K Lapphra, Y Sabmee… - 2017 - bionet-asia.com
Background Increasing evidence shows that protection induced by acellular pertussis
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease. We …

[HTML][HTML] Factors associated with testing for HIV and other sexually transmitted infections in men who have sex with men and transgender women in Bangkok, Thailand

TA Crowell, S Nitayaphan, N Sirisopana… - AIDS Research and …, 2022 - Springer
Background Routine screening for HIV and other sexually transmitted infections (STIs) facilitates
early diagnosis and treatment, thereby preventing morbidity and onward transmission. …

Late Boosting of the RV144 Regimen Improves the Magnitude and Quality of Immune Responses

P Pitisuttithum, S Nitayapha, S Chariyalertsak… - 2019 - papers.ssrn.com
Background: The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521)
and AIDSVAX® B/E administration over six months resulted in a 31% efficacy in …